Please use this identifier to cite or link to this item:
|Title:||Activated NKT cells can condition different splenic dendritic cell subsets to respond more effectively to TLR engagement and enhance cross-priming||Authors:||Osmond, T. L.
Petersen, Troels R.
Hermans, Ian F.
Farrand, K. J.
Painter, G. F.
|Keywords:||DRNTU::Science::Biological sciences::Microbiology::Immunology||Issue Date:||2015||Source:||Osmond, T. L., Farrand, K. J., Painter, G. F., Ruedl, C., Petersen, T. R., & Hermans, I. F. (2015). Activated NKT cells can condition different splenic dendritic cell subsets to respond more effectively to TLR engagement and enhance cross-priming. The Journal of Immunology, 195(3), 821-831.||Series/Report no.:||The journal of immunology||Abstract:||The function of dendritic cells (DCs) can be modulated through multiple signals, including recognition of pathogen-associated molecular patterns, as well as signals provided by rapidly activated leukocytes in the local environment, such as innate-like T cells. In this article, we addressed the possibility that the roles of different murine DC subsets in cross-priming CD8+ T cells can change with the nature and timing of activatory stimuli. We show that CD8α+ DCs play a critical role in cross-priming CD8+ T cell responses to circulating proteins that enter the spleen in close temporal association with ligands for TLRs and/or compounds that activate NKT cells. However, if NKT cells are activated first, then CD8α− DCs become conditioned to respond more vigorously to TLR ligation, and if triggered directly, these cells can also contribute to priming of CD8+ T cell responses. In fact, the initial activation of NKT cells can condition multiple DC subsets to respond more effectively to TLR ligation, with plasmacytoid DCs making more IFN-α and both CD8α+ and CD8α− DCs manufacturing more IL-12. These results suggest that different DC subsets can contribute to T cell priming if provided appropriately phased activatory stimuli, an observation that could be factored into the design of more effective vaccines.||URI:||https://hdl.handle.net/10356/96360
|DOI:||http://dx.doi.org/10.4049/jimmunol.1401751||Rights:||© 2015 American Association of Immunologists.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SBS Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.